Annexon SEC filings document a clinical-stage biopharmaceutical company developing C1q-targeted immunotherapies for neuroinflammatory and classical complement-mediated diseases. Its Form 8-K reports furnish operating results, portfolio progress, investor presentations, and strategic priority updates tied to programs such as vonaprument, tanruprubart, and ANX1502.
The company’s filings also cover proxy governance, annual meeting proposals, director elections, auditor ratification, executive compensation votes, board changes, and Nasdaq-listed common stock. Capital-structure disclosures include amendments to common stock purchase warrants and related rights of security holders.
Annexon, Inc. is soliciting proxies for its 2026 Annual Meeting to be held virtually on June 11, 2026. The Board asks stockholders to vote on: election of two Class III directors, ratification of KPMG as auditor, an advisory say-on-pay vote, and an amendment to increase authorized common stock from 300,000,000 to 500,000,000 shares. The record date for voting is April 13, 2026 and there were 162,507,278 shares outstanding on that date. The proxy includes disclosure of director nominees, board committees, executive officers, 2025 executive compensation, equity awards and the Board’s recommendation to vote “For” each proposal.
Annexon, Inc. director William H. Carson reported buying additional company stock. On April 10, 2026, he made an open-market purchase of 8,000 shares of common stock at $6.20 per share, bringing his direct holdings to 70,405 shares of Annexon common stock.
The filing notes that this transaction was executed under Carson’s Rule 10b5-1 trading plan, adopted on December 8, 2025, indicating the trade was pre-scheduled rather than a discretionary market-timing decision.
Annexon, Inc. is a clinical-stage biopharma company developing targeted immunotherapies for complement‑mediated neuroinflammatory diseases of the body, brain and eye.
The company’s late-stage programs include tanruprubart for Guillain‑Barré Syndrome, vonaprument for geographic atrophy in dry AMD, and oral candidate ANX1502 for autoimmune conditions, all built around inhibition of the classical complement pathway, particularly C1q and C1s.
Annexon reports it will need substantial additional financing, has no approved products, and is advancing multiple precision-medicine programs while relying on third‑party manufacturers and extensive patent protection for its platform and pipeline.
Annexon, Inc. furnished an update on its fourth quarter and full-year 2025 results alongside progress across its late-stage neuroinflammatory pipeline. The company is advancing three key programs: vonaprument for geographic atrophy, tanruprubart for Guillain-Barré syndrome, and oral C1 inhibitor ANX1502 for autoimmune disease.
Vonaprument’s pivotal Phase 3 ARCHER II trial in geographic atrophy has completed enrollment, with topline data expected in the fourth quarter of 2026. Tanruprubart has an MAA filed in Europe for GBS, with the US/EU FORWARD study intended to support a planned BLA submission in 2026.
Annexon reported cash, cash equivalents and short-term investments of $238.3 million as of December 31, 2025, and expects its operating runway to extend into the second half of 2027. For 2025, R&D expenses were $184.7 million and G&A expenses were $31.7 million, leading to a net loss attributable to common stockholders of $208.5 million, or $1.34 per share.
Annexon Inc: Amendment to a Schedule 13G filed by The Vanguard Group reports 0 shares beneficially owned and 0% of common stock following an internal realignment effective January 12, 2026. The amendment states certain Vanguard subsidiaries will report ownership separately in reliance on SEC Release No. 34-39538.
The filing is signed by Vanguard's Head of Global Fund Administration and lists Vanguard's Malvern, PA address; it clarifies that Vanguard and its managed accounts have the right to receive dividends or proceeds but that no single other person holds more than 5% of the class.
Annexon, Inc. director William H. Carson reported an open-market purchase of 8,000 shares of Common Stock at $5.67 per share. Following this transaction, he directly owns 62,405 shares. The filing notes the trade was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 8, 2025.
Annexon, Inc.’s chief medical officer, Jamie Dananberg, reported an open-market sale of 5,820 shares of common stock. The shares were sold to cover tax withholding obligations related to vesting restricted stock units. After this tax-related sale, Dananberg still holds 123,582 Annexon common shares directly.
Annexon, Inc. executive Michael Overdorf, EVP & Chief Business Officer, reported an open-market sale of 4,339 shares of common stock at a weighted average price of $5.42 per share. The filing states the shares were sold to cover tax withholding obligations related to vesting restricted stock units. After this transaction, Overdorf beneficially owns 182,625 shares of Annexon common stock directly.
Annexon, Inc. executive vice president and chief innovation officer Ted Yednock reported an open-market sale of 5,566 shares of common stock at a weighted average price of $5.42 per share on March 2, 2026. The sale was made to cover tax withholding obligations from vesting RSUs, leaving him with 154,161 directly owned shares.
Annexon, Inc. executive vice president and chief scientific officer Dean Richard Artis sold 5,894 shares of common stock on March 2, 2026 in an open-market transaction to cover tax withholding obligations from vested restricted stock units. The weighted average sale price was $5.43 per share, and he held 180,093 shares afterward.